本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net）参与本次互动交流，活动时间为 2025 年 9 月 19 日（周五） 15:30-17:00。 届时公司董事长潘伟潮先生、总经理潘志刚先生、董事会秘书李薇女士、财 务总监吴蓉女士将在线就公司 2025 年半年度业绩、公司治理、发展战略、经营 状况、融资计划、股权激励和可持续发展等投资者关心的问题，与投资者进行沟 通与交流，欢迎广大投资者踊跃参与！ 特此公告。 广东乐心医疗电子股份有限公司 董事会 乐心医疗 2025 年公告 证券代码：300562 证券简称：乐心医疗 公告编号：2025-099 广东乐心医疗电子股份有限公司 关于参加2025年广东辖区投资者网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，广东乐心医疗电子股份有限公司（以下 简称"公司"）将参加由广东证监局、广东上市公司协会与深圳市全景网络有限 公司联合举办的"向新提质 价值领航——2025 年广东辖区投资者集体接待日 活动"，现将相关事项 ...

Group 1 - The core point of the news is the resignation of Huang Linxiang as the employee representative director and CFO of Le Xin Medical due to personal reasons, and the appointment of Wu Rong as the new CFO [1] - Le Xin Medical's revenue composition for the first half of 2025 is as follows: home medical products account for 66.29%, electronic health scales account for 24.17%, other products account for 7.55%, and wearable sports wristbands account for 1.99% [1] - As of the report date, Le Xin Medical has a market capitalization of 3.2 billion yuan [1] Group 2 - Related news includes the resignation of Yi Bingmin from Gao Le Co. as CFO and Vice General Manager [2] - Zhao Bin's resignation as Vice President and CFO of Yingxin Development is also noted [2] - Chen Feng Technology has appointed Dong Jianzao as the new CFO [2]

Core Viewpoint - The resignation of Huang Linxiang from all positions at Lexin Medical marks a significant leadership change, with Wu Rong appointed as the new CFO, indicating a shift in the company's financial management strategy [1][2]. Group 1: Personnel Changes - Huang Linxiang has resigned from all positions, including CFO, employee representative director, and committee member, effective September 9, 2025 [2]. - Huang held 95,000 shares in the company, including 40,000 restricted shares from the 2023 incentive plan, which will be repurchased and canceled by the company [2]. - Wu Rong, previously a member of the fourth supervisory board, has been appointed as the new CFO, bringing extensive experience in financial management within the company [2][3]. Group 2: Financial Performance - In the first half of 2025, Lexin Medical reported a revenue of 521 million yuan, representing a year-on-year growth of 4.57% [3]. - The net profit attributable to shareholders for the same period was 42 million yuan, showing a year-on-year increase of 21.35% [3].

Market Overview - The Shanghai Composite Index closed at 3855.10 points, above the six-month moving average, with an increase of 1.12% [1] - The total trading volume of A-shares reached 14961.95 billion yuan [1] Stocks Breaking Six-Month Moving Average - A total of 118 A-shares have surpassed the six-month moving average today [1] - Notable stocks with significant deviation rates include: - Xinxiangwei (688593) with a deviation rate of 18.44% and a price increase of 20.00% [1] - Fabon Information (300925) with a deviation rate of 11.71% and a price increase of 13.31% [1] - Aerospace Engineering (603698) with a deviation rate of 8.55% and a price increase of 10.01% [1] Additional Stocks with Minor Deviations - Stocks with smaller deviation rates that have just crossed the six-month moving average include: - Huatushan (300492) with a deviation rate of 8.31% and a price increase of 10.82% [1] - Leidi Technology (300652) with a deviation rate of 6.06% and a price increase of 8.27% [1] - Tianshan Electric (301379) with a deviation rate of 4.05% and a price increase of 4.14% [1]

Group 1 - The core point of the article is that 乐心医疗 (Lixun Medical) has disclosed the draft of its "Key Stone No. 1" employee stock ownership plan, which aims to involve a maximum of 25 participants [1] - The employee stock ownership plan intends to hold a maximum of 912,200 shares, with a total fundraising cap of 6.9419 million yuan [1] - The duration of the employee stock ownership plan is set for 48 months, with different lock-up periods of 12 months and 24 months for the acquired shares [1]

Core Viewpoint - Le Xin Medical (300562.SZ) has disclosed a draft for its 2025 stock option incentive plan, aiming to motivate its employees through stock options [1] Group 1: Stock Option Details - The company plans to grant a total of 2 million stock options to 40 incentive recipients [1] - The exercise price for the stock options is set at 15.21 yuan per option [1] - The validity period of the incentive plan is from the date of stock option authorization until all granted options are exercised or canceled, with a maximum duration of 36 months [1]

Group 1 - The core point of the article is that 乐心医疗 (Leksin Medical) has disclosed the draft of its "基石1号" employee stock ownership plan, which involves a maximum of 25 participants and aims to hold up to 912,200 shares [1] - The total amount of funds to be raised by this employee stock ownership plan is capped at 6.9419 million yuan [1] - The duration of the employee stock ownership plan is set for 48 months, with different lock-up periods for the acquired shares, specifically 12 months and 24 months, starting from the date the plan is approved by the company's shareholders' meeting [1]

Core Viewpoint - 乐心医疗 has announced a stock option incentive plan for 2025, aiming to motivate its employees through equity participation [1] Summary by Categories Stock Option Plan - The company plans to grant a total of 2 million stock options to 40 incentive recipients [1] - The exercise price for the stock options is set at 15.21 yuan per option [1] - The validity period of the incentive plan is from the date of stock option authorization until all granted options are exercised or canceled, with a maximum duration of 36 months [1]

Core Viewpoint - Recent actions by the company regarding its stock incentive plan include the repurchase and cancellation of restricted stocks for a departing employee, along with adjustments to the second vesting period of the 2023 stock incentive plan [1][3]. Group 1: Incentive Plan Implementation History - On July 24, 2023, the company’s Compensation and Assessment Committee proposed the draft of the incentive plan, which was later approved by the board on July 26, 2023 [2]. - The company publicly announced the list of incentive recipients and held a temporary shareholders' meeting on August 18, 2023, to approve related resolutions [2]. - Subsequent meetings in 2024 and 2025 involved discussions and approvals regarding adjustments to grant prices and conditions for lifting restrictions on the stocks [2]. Group 2: Details of Repurchase and Cancellation - The repurchase and cancellation of restricted stocks are triggered by the departure of an incentive recipient, who no longer meets the incentive conditions [3]. - The repurchase price will be at the grant price, and the funds for this repurchase will come from the company’s own resources [4]. Group 3: Adjustments to Lifting Restrictions - Originally, two individuals were eligible to lift restrictions on 1.04 million shares, but due to the departure of one individual, the number of eligible individuals is now one, and the shares eligible for lifting restrictions have been adjusted to 1 million [5]. - Legal opinions confirm that the repurchase and adjustment of lifting restrictions have received necessary authorizations and approvals, although final approval from the shareholders' meeting is still required [5].

Company Changes - Huang Linxiang resigned from her positions as employee representative director and CFO due to personal reasons, and will no longer hold any positions in the company or its subsidiaries [1] - Wu Rong has been appointed as the new CFO after being nominated by the general manager and approved by the board's nomination and audit committees [1] Financial Performance - For the first half of 2025, the revenue composition of the company is as follows: home medical products accounted for 66.29%, electronic health scales for 24.17%, others for 7.55%, and wearable fitness bands for 1.99% [1] - The current market capitalization of the company is 3.2 billion yuan [1]